Paes B, Lanari M, Rodgers-Gray B, Fullarton J, Carbonell-Estrany X
Front Pediatr. 2024; 12:1343960.
PMID: 38283631
PMC: 10811053.
DOI: 10.3389/fped.2024.1343960.
Mineva G, Purtill H, Dunne C, Philip R
BMJ Glob Health. 2023; 8(2).
PMID: 36746518
PMC: 9906265.
DOI: 10.1136/bmjgh-2022-009693.
Butt M, Elliott L, Guy F, Symington A, Paes B
Front Pediatr. 2023; 10:997349.
PMID: 36683806
PMC: 9851620.
DOI: 10.3389/fped.2022.997349.
Tso C, Lam C, Calvert J, Mao Q
Front Pediatr. 2022; 10:886212.
PMID: 35989982
PMC: 9385995.
DOI: 10.3389/fped.2022.886212.
Jourdain M, Benchaib M, Ploin D, Gillet Y, Javouhey E, Horvat C
Vaccines (Basel). 2022; 10(5).
PMID: 35632484
PMC: 9147066.
DOI: 10.3390/vaccines10050729.
Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies.
Lanari M, Anderson E, Sheridan-Pereira M, Carbonell-Estrany X, Paes B, Rodgers-Gray B
Epidemiol Infect. 2020; 148:e170.
PMID: 32799945
PMC: 7439292.
DOI: 10.1017/S0950268820001661.
RSV hospitalization in infancy increases the risk of current wheeze at age 6 in late preterm born children without atopic predisposition.
Korsten K, Blanken M, Buiteman B, Nibbelke E, Naaktgeboren C, Bont L
Eur J Pediatr. 2019; 178(4):455-462.
PMID: 30637465
DOI: 10.1007/s00431-018-03309-0.
Hospitalisation of late preterm infants due to lower respiratory tract infections in Lithuania, Latvia, and Estonia: incidence, disease severity, and risk factors.
Drazdiene N, Tameliene R, Kviluna D, Saik P, Saik E, Zaikauskiene J
Acta Med Litu. 2018; 25(2):76-85.
PMID: 30210241
PMC: 6130930.
DOI: 10.6001/actamedica.v25i2.3760.
Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.
Maksic H, Heljic S, Skokic F, Sumanovic-Glamuzina D, Milosevic V, Zlatanovic A
Bosn J Basic Med Sci. 2018; 18(3):279-288.
PMID: 29750895
PMC: 6087550.
DOI: 10.17305/bjbms.2018.2318.
Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.
Shahabi A, Peneva D, Incerti D, McLaurin K, Stevens W
Pharmacoecon Open. 2018; 2(1):53-61.
PMID: 29464672
PMC: 5820240.
DOI: 10.1007/s41669-017-0042-3.
Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants.
Blanken M, Paes B, Anderson E, Lanari M, Sheridan-Pereira M, Buchan S
Pediatr Pulmonol. 2018; 53(5):605-612.
PMID: 29405612
PMC: 6099524.
DOI: 10.1002/ppul.23960.
Respiratory syncytial virus in Brazilian infants - Ten years, two cohorts.
Wollmeister E, Alvarez A, Bastos J, Marson F, Ribeiro J, Baracat E
J Clin Virol. 2017; 98:33-36.
PMID: 29227860
PMC: 7106499.
DOI: 10.1016/j.jcv.2017.12.002.
Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.
Blanken M, Frederix G, Nibbelke E, Koffijberg H, Sanders E, Rovers M
Eur J Pediatr. 2017; 177(1):133-144.
PMID: 29168012
PMC: 5748402.
DOI: 10.1007/s00431-017-3046-1.
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.
Parikh R, McLaurin K, Margulis A, Mauskopf J, Ambrose C, Pavilack M
Infect Dis Ther. 2017; 6(4):477-486.
PMID: 28866800
PMC: 5700888.
DOI: 10.1007/s40121-017-0167-9.
Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
Cetinkaya M, Oral T, Karatekin S, Cebeci B, Babayigit A, Yesil Y
Eur J Clin Microbiol Infect Dis. 2017; 36(9):1629-1634.
PMID: 28391538
DOI: 10.1007/s10096-017-2976-x.
Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.
Simoes E, Anderson E, Wu X, Ambrose C
PLoS One. 2016; 11(11):e0166226.
PMID: 27898687
PMC: 5127494.
DOI: 10.1371/journal.pone.0166226.
Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.
Anderson E, Carbonell-Estrany X, Blanken M, Lanari M, Sheridan-Pereira M, Rodgers-Gray B
Pediatr Infect Dis J. 2016; 36(2):160-167.
PMID: 27755464
PMC: 5242218.
DOI: 10.1097/INF.0000000000001377.
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease.
Figueras-Aloy J, Manzoni P, Paes B, Simoes E, Bont L, Checchia P
Infect Dis Ther. 2016; 5(4):417-452.
PMID: 27628014
PMC: 5125133.
DOI: 10.1007/s40121-016-0130-1.
The Role of Human Milk Immunomodulators in Protecting Against Viral Bronchiolitis and Development of Chronic Wheezing Illness.
Dixon D
Children (Basel). 2016; 2(3):289-304.
PMID: 27417364
PMC: 4928768.
DOI: 10.3390/children2030289.
Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).
Stranak Z, Saliba E, Kosma P, Posfay-Barbe K, Yunis K, Farstad T
PLoS One. 2016; 11(6):e0157446.
PMID: 27310438
PMC: 4910988.
DOI: 10.1371/journal.pone.0157446.